Peer-Reviewed Journal Details
Mandatory Fields
Fitzgerald, P;Mandel, A;Bolton, AE;Sullivan, AM;Nolan, Y
2008
December
Behavioural Brain Research
Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition: Implications for Parkinson's disease
Validated
WOS: 11 ()
Optional Fields
ALPHA-SYNUCLEIN NEURODEGENERATIVE DISEASES MODEL PATHOGENESIS IMPAIRMENT PATHWAYS SYSTEM TARGET BRAIN
195
271
274
Failure of the ubiquitin-proteasome system to degrade abnormal proteins may underlie the accumulation of alpha-synuclein and dopaminergic neuronal degeneration that occurs in Parkinson's disease. Consequently, a reduction of functional proteasome activity has been implicated in Parkinson's disease. VP025 (Vasogen Inc.) is a preparation of phospholipid nanoparticles incorporating phosphatidylglycerol that has been shown to have neuroprotective effects. We show that VP025 prevents the deficits in motor coordination and dopamine observed in a proteasome inhibitor rat model of PD. Thus, VP025 may have a therapeutic effect on the impairment of dopaminergic-mediated motor activity induced by proteasome inhibition. (c) 2008 Elsevier B.V. All rights reserved.
AMSTERDAM
0166-4328
10.1016/j.bbr.2008.08.041
Grant Details